Literature DB >> 923094

Selective protamine sulphate inactivation of lipoprotein lipase and hepatic lipase in human post-heparin plasma: specific lipase levels in normals and in type I hyperlipoproteinaemia.

G M Berger, P R Abraham.   

Abstract

The rate of inactivation of triglyceride hydrolase activity by protamine sulphate was determined in pooled, normal, post-heparin plasma. Two distinct first-order rates of inactivation were obtained and the derived constants used to calculate the lipoprotein lipase and hepatic lipase contributions to the total post-heparin triglyceride hydrolase activity in normal controls and in patients with familial hyperchylomicronaemia. The lipoprotein lipase was reduced in the patients whereas the hepatic lipase was normal. There was however a marked age-related increase in the hepatic enzyme activity in normal subjects. Post-heparin lipolytic activity, assayed in vitro against lipoproteins of d less than 1.006 derived from the patients, was markedly reduced in our hyperchylomicronaemic subjects. This assay correlated well with the lipoprotein lipase activity determined by selective protamine sulphate inactivation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 923094     DOI: 10.1016/0009-8981(77)90052-3

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Association of a DNA polymorphism in the apolipoprotein C-III gene with diverse hyperlipidaemic phenotypes.

Authors:  H E Henderson; S V Landon; J Michie; G M Berger
Journal:  Hum Genet       Date:  1987-01       Impact factor: 4.132

2.  The Toxicokinetic Profile of Dex40-GTMAC3-a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin.

Authors:  Emilia Sokolowska; Bartlomiej Kalaska; Kamil Kaminski; Alicja Lewandowska; Agnieszka Blazejczyk; Joanna Wietrzyk; Irena Kasacka; Krzysztof Szczubialka; Dariusz Pawlak; Maria Nowakowska; Andrzej Mogielnicki
Journal:  Front Pharmacol       Date:  2016-03-17       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.